Rein Therapeutics Postpones Annual Meeting Due to Low Shareholder Turnout

Rein Therapeutics (NASDAQ: RNTX) announced the adjournment of its 2025 Annual Meeting of Stockholders originally scheduled for June 24, 2025.

Rhea-AI Filing Summary

Rein Therapeutics (NASDAQ: RNTX) announced the adjournment of its 2025 Annual Meeting of Stockholders originally scheduled for June 24, 2025. The meeting has been rescheduled to July 23, 2025 due to failure to achieve a quorum.

Key details of the adjournment:

• Original meeting date: June 24, 2025
• New meeting date: July 23, 2025
• Record date remains: May 5, 2025
• Purpose: To allow additional time for stockholders to vote on proposals outlined in the proxy statement filed May 12, 2025

The Form 8-K was filed by President and CEO Brian Windsor, Ph.D. from the company's Austin, Texas headquarters. This development indicates potential challenges in securing sufficient shareholder participation for important corporate governance matters.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did RNTX adjourn its 2025 Annual Meeting?

RNTX adjourned its 2025 Annual Meeting, originally scheduled for June 24, 2025, because a quorum was not achieved. The meeting has been rescheduled to July 23, 2025, to allow stockholders more time to vote on the proposals outlined in the Company's May 12, 2025 proxy statement.

When is RNTX's rescheduled 2025 Annual Meeting?

RNTX's rescheduled 2025 Annual Meeting will take place on Wednesday, July 23, 2025. The record date remains unchanged at the close of business on May 5, 2025.

What is the record date for RNTX's 2025 Annual Meeting?

The record date for RNTX's 2025 Annual Meeting is the close of business on May 5, 2025. This date remains unchanged despite the meeting's adjournment.

When did RNTX file its proxy statement for the 2025 Annual Meeting?

RNTX filed its definitive proxy statement with the Securities and Exchange Commission on May 12, 2025, containing the proposals to be voted on at the Annual Meeting.

Who is the current CEO of RNTX?

Brian Windsor, Ph.D. serves as the President and Chief Executive Officer of Rein Therapeutics, Inc., as evidenced by his signature on the June 24, 2025 8-K filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/24/2025 - 04:01 PM Learn about SEC filing dates

NASDAQ false 0001420565 0001420565 2025-06-24 2025-06-24

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 24, 2025

Rein Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware		001-38130		13-4196017
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

12407 N. Mopac Expy., Suite 250 #390
Austin, Texas				78758
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s telephone number, including area code: (737) 802-1989

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		RNTX		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On June 24, 2025, Rein Therapeutics, Inc. (the “Company”) announced that it adjourned the Company’s 2025 Annual Meeting of Stockholders (the “Annual Meeting”), scheduled to take place on Tuesday, June 24, 2025, until Wednesday, July 23, 2025, due to the fact that a quorum was not achieved and to allow more opportunity for Company stockholders to vote on all proposals described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on May 12, 2025. The record date for the Annual Meeting continues to be the close of business on May 5, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				REIN THERAPEUTICS, INC.
Date: June 24, 2025				By:		/s/ Brian Windsor
						Brian Windsor, Ph.D.
						President and Chief Executive Officer